Breaking Resistance, Shaping the Future | Editorial Board Voices (Episode 1)

Prof. Godefridus J. Peters Reflects on Eight Years of Cancer Drug Resistance and the Future of the Field

As part of Breaking Resistance, Shaping the Future, a scientific series celebrating the eighth anniversary of Cancer Drug Resistance (CDR), the journal is pleased to launch Editorial Board Voices, a new interview series spotlighting Editorial Board members and leading experts from around the world.

The inaugural episode features Professor Godefridus J. Peters, Editor-in-Chief of CDR and an internationally recognized expert in cancer pharmacology and drug resistance research.

In this wide-ranging conversation, Prof. Peters reflects on the motivation behind founding CDR, the journal's achievements over the past eight years, the evolution of the field, and the scientific challenges expected to shape the next decade. He also discusses the importance of translational research, shares advice for early-career researchers, and outlines his vision for the journal's future.

Watch the Full Interview

Interview Highlights

• Why was Cancer Drug Resistance founded?
• The journal's most significant achievement over the past eight years
• How cancer drug resistance research has evolved from chemotherapy to immunotherapy
• Why understanding immunotherapy resistance is one of the next major frontiers
• The essential role of translational research in improving patient outcomes
• Advice for the next generation of cancer researchers
• Prof. Peters' vision for Cancer Drug Resistance over the coming decade

Key Takeaways

Building a Journal for a Growing Field

Prof. Peters explains that CDR was founded to provide a dedicated platform for cancer drug resistance research, bringing together basic, translational, and clinical studies while maintaining high scientific standards.

Where the Field Is Heading

Ranging from chemotherapy resistance to immunotherapy and combination therapies, the field has evolved rapidly. Prof. Peters identifies resistance to immunotherapy, as well as the interplay between chemotherapy and immunotherapy, as among the most important research priorities for the next decade.

Looking Ahead

Prof. Peters emphasizes that high-quality science, translational research, openness to new ideas, and continued support for early-career investigators will remain central to both the journal and the broader research community.

This interview marks the first episode of the Editorial Board Voices series. Stay tuned for upcoming conversations with Editorial Board members and leading experts as we continue to explore the theme Breaking Resistance, Shaping the Future.

Editor: Louise Pan
Language Editor: Amir Khan
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Cancer Drug Resistance